VolitionRx Ltd
VNRX
34 hedge funds and large institutions have $15.1M invested in VolitionRx Ltd in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 7 closing their positions.
218% more call options, than puts
Call options by funds: $308K | Put options by funds: $97K
88% more capital invested
Capital invested by funds: $8.02M → $15.1M (+$7.03M)
0.02% more ownership
Funds ownership: 0.51% → 0.54% (+0.02%)
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIM
Lagoda Investment Management
New York
|
+$967K |
| 2 |
CPA
Cowen Prime Advisors
New York
|
+$156K |
| 3 |
SAMC
Spectrum Asset Management (California)
Newport Beach,
California
|
+$108K |
| 4 |
Cerity Partners
New York
|
+$73.8K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$57.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$246K |
| 2 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$201K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$51.4K |
| 4 |
VF
Virtu Financial
New York
|
-$51K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$42.6K |
VNRX Hedge Fund Activity: Q4 2022 in Review
34 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in VolitionRx Ltd (VNRX) for Q4 2022, worth a combined $15.1M — up 88% from $8.02M a quarter earlier.
Fund positioning in VNRX was balanced in Q4 2022: 7 funds opened new positions, 7 closed out, 6 added to existing stakes and 10 trimmed.
The largest buyer was Lagoda Investment Management, adding an estimated $967K. The largest seller was Morgan Stanley, cutting an estimated $246K.
- 34 institutional investors held VolitionRx Ltd (VNRX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $15.1M of VolitionRx Ltd stock for Q4 2022, up 88% quarter-over-quarter.
- 7 funds opened new VolitionRx Ltd positions in Q4 2022 and 7 closed out, a net change of 0 holders.
- The largest VolitionRx Ltd buyer in Q4 2022 was Lagoda Investment Management, an estimated $967K added.
- The largest VolitionRx Ltd seller in Q4 2022 was Morgan Stanley, an estimated $246K sold.
Based on aggregated 13F filings for Q4 2022.